The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized, Double-Blind, Multicenter Study
Abstract
Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Inadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805
Nosocomial infections in medical intensive care units in the United States
Richards, M. J., Edwards, J. R., Culver, D. H., & Gaynes, R. P. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00020 · Cited by 1,565
Impact of BAL Data on the Therapy and Outcome of Ventilator-Associated Pneumonia
Luna, C. M., Vujacich, P., Niederman, M. S., Vay, C., Gherardi, C., Matera, J., & Jolly, E. C. (1997) · Chest · doi:10.1378/chest.111.3.676 · Cited by 916
Ventilator-associated Pneumonia Caused by Potentially Drug-resistant Bacteria
TROUILLET, J.-L., CHASTRE, J., VUAGNAT, A., JOLY-GUILLOU, M.-L., COMBAUX, D., DOMBRET, M.-C., & GIBERT, C. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.2.9705064 · Cited by 885
(1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.5.8630626 · Cited by 830
Methicillin-Resistant Staphylococcus aureus in U.S. Hospitals, 1975–1991
Panlilio, A. L., Culver, D. H., Gaynes, R. P., Banerjee, S., Henderson, T. S., Tolson, J. S., Martone, W. J., & System, N. N. I. S. (1992) · Infection Control & Hospital Epidemiology · doi:10.1086/646432 · Cited by 657
Alvarez-Lerma, F., & ICU-Acquired Pneumonia Study Group (1996) · Intensive Care Medicine · doi:10.1007/bf01712153 · Cited by 652
Brickner, S. J., Hutchinson, D. K., Barbachyn, M. R., Manninen, P. R., Ulanowicz, D. A., Garmon, S. A., Grega, K. C., Hendges, S. K., Toops, D. S., Ford, C. W., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9509556 · Cited by 582
Guideline for Prevention of Nosocomial Pneumonia
Tablan, O. C., Anderson, L. J., Arden, N. H., Breiman, R. F., Butler, J. C., McNeil, M. M., & The Hospital Infection Control Practices Advisory Committee (1994) · Infection Control and Hospital Epidemiology · doi:10.2307/30147436 · Cited by 500
The Influence of Mini-BAL Cultures on Patient Outcomes
MD, M. H. K., & Ward, S. (1998) · Chest · doi:10.1378/chest.113.2.412 · Cited by 494
Fink, M. P., Snydman, D. R., Niederman, M. S., Leeper, K. V., Johnson, R. H., Heard, S. O., Wunderink, R. G., Caldwell, J. W., Schentag, J. J., & Siami, G. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.547 · Cited by 461
Self-citationIn vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
Rello, J., Torres, A., Ricart, M., Valles, J., Gonzalez, J., Artigas, A., & Rodriguez-Roisin, R. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.6.7952612 · Cited by 425
LEU, H.-S., KAISER, D. L., MORI, M., WOOLSON, R. F., & WENZEL, R. P. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115245 · Cited by 417
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions
Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H., Melchior, E. P., Swaney, S. M., Dunyak, D. S., Demyan, W. F., & Buysse, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2132 · Cited by 384
RELLO, J., SA-BORGES, M., CORREA, H., LEAL, S.-R., & BARAIBAR, J. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.9812034 · Cited by 352
Nosocomial infection surveillance, 1984.
Horan, T. C., Jw, W., Wr, J., Emori, T. G., Culver, D. H., Munn, V. P., Thornsberry, C., Dr, O., & Jm, H. (1986) · PubMed · Cited by 342
Epidemiology of Nosocomial Pneumonia
Craven, D. E., & Steger, K. A. (1995) · Chest · doi:10.1378/chest.108.2_supplement.1s · Cited by 265
Guideline for Prevention of Nosocomial Pneumonia
Tablan, O. C., Anderson, L. J., Arden, N. H., Breiman, R. P., Butler, J. C., McNeil, M. M., & The Hospital Infection Control Practices Advisory Committee (1994) · Infection Control & Hospital Epidemiology · doi:10.1086/646989 · Cited by 239
Preventing nosocomial pneumonia: State of the art and perspectives for the 1990s
Craven, D. E., Steger, K. A., & Barber, T. W. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90343-v · Cited by 222
FAGON, J.-Y., PATRICK, H., HAAS, D. W., TORRES, A., GIBERT, C., CHEADLE, W. G., FALCONE, R. E., ANHOLM, J. D., PAGANIN, F., FABIAN, T. C., et al. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.3.9904115 · Cited by 214
Self-citationTextbook of Pulmonary Diseases
(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-10-862_1 · Cited by 211
Nosocomial infection surveillance.
Sj, T., & Elder, H. A. (1979) · PubMed · Cited by 206
Risk Factors for ICU-Acquired Pneumonia
Cook, D. J. (1998) · JAMA · doi:10.1001/jama.279.20.1605 · Cited by 190
Effect of intensive care unit nosomial pneumonia on duration of stay and mortality
Craig, C. P., & Connelly, S. (1984) · American Journal of Infection Control · doi:10.1016/0196-6553(84)90114-7 · Cited by 176
Oxazolidinone Antibacterial Agents
Brickner, S. J. (1996) · Current Pharmaceutical Design · doi:10.2174/1381612802666220921173820 · Cited by 171
The in-vitro activity of linezolid (U-100766) and tentative breakpoints
Wise, R. A., Andrews, J. M., Boswell, F. J., & Ashby, J. P. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.6.721 · Cited by 149
Rybak, M. J., Cappelletty, D. M., Moldovan, T., Aeschlimann, J. R., & Kaatz, G. W. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.721 · Cited by 147
Interactions of monoamine oxidase with substrates and inhibitors
Dostert, P., Benedetti, M. S., & Tipton, K. F. (1989) · Medicinal Research Reviews · doi:10.1002/med.2610090104 · Cited by 144
Dresser, L., & Rybak, M. J. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03109.x · Cited by 143
Ford, C. W., Hamel, J. C., Wilson, D. M., Moerman, J. K., Stapert, D., Yancey, R. J., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.6.1508 · Cited by 140
HOSPITAL-ACQUIRED PNEUMONIA: EPIDEMIOLOGY, ETIOLOGY, AND TREATMENT
McEachern, R., & Campbell, G. D. (1998) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70209-9 · Cited by 112
EPIDEMIOLOGY OF NOSOCOMIAL PNEUMONIA IN INTENSIVE CARE UNIT PATIENTS
George, D. L. (1995) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(21)00977-1 · Cited by 100
Rubinstein, E., Lode, H. M., Grassi, C., & Antibiotic Study Group (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.5.1217 · Cited by 85
Self-citationBoyce, J. M. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.151.6.1109 · Cited by 83
Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors
Matassova, N., Rodnina, M. V., Endermann, R., Kroll, H., Pleiß, U., Wild, H., & Wintermeyer, W. (1999) · RNA · doi:10.1017/s1355838299990210 · Cited by 75
Overview of Resistance in the 1990s
File, T. M. (1999) · CHEST Journal · doi:10.1378/chest.115.suppl_1.3s · Cited by 74
Jorgensen, J. H., McElmeel, M. L., & Trippy, C. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.465 · Cited by 71
Nosocomial Pneumonia in Medicare Patients
Boyce, J. M. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400060053009 · Cited by 61
Ml, C., Sc, C., Hj, P., Hsueh, P., Ls, Y., Sw, H., & Kt, L. (1999) · PubMed · Cited by 37
Nosocomial pneumonia in the medical and surgical patient: Risk Factors and Primary Management
Nogare, A. R. D. (1994) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30121-3 · Cited by 31
Anthonisen, N. R. (1999) · CHEST Journal · doi:10.1378/chest.115.1.3 · Cited by 30
Hospital-acquired pneumonia: methicillin resistance and intensive care unit admission
Fagon, J.-Y., Maillet, J.-M., & Novara, A. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00151-x · Cited by 30
The diagnosis and treatment challenges in nosocomial pneumonia
Baughman, R. P., Tapson, V. F., & McIvor, A. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00161-8 · Cited by 24
Bird's-eye view of nosocomial infections in medical ICU: Blue bugs, fungi, and device-days
Bonten, M. J. M., & Weinstein, R. A. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00001 · Cited by 16
Cited by
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Metadata
- Authors
- Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., & the Linezolid Nosocomial Pneumonia Study Group
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-02-01
- Volume
- 32
- Issue
- 3
- Pages
- 402-412
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2128076923
- Cited by
- 440
- References
- 46
- FWCI
- 30.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.